Ownership and insider activity for Milestone Pharmaceuticals Inc. (MIST): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development.
Price
| Price | $0.89 |
| Market Cap | $111M |
| Exchange | NASDAQ |
| Country | CA |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $10.9M | $85.9M | $119.8M | $72.3M | $114.1M | $7.6M | $13.8M | $25.3M | $73.0M |
| Short-term Investments | $16.0M | $29000 | 0 | $70.0M | 0 | $56.9M | $52.2M | $44.4M | $32.9M |
| Receivables | $543000 | $677000 | $836000 | $948000 | $483000 | $1.2M | $3.9M | $2.4M | $3.5M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $648000 |
| Total Current Assets | $27.6M | $88.1M | $122.5M | $148.7M | $118.9M | $71.8M | $73.0M | $73.9M | $111.9M |
| Property, Plant & Equipment | $35000 | $30000 | $929000 | $1.3M | $926000 | $2.7M | $2.2M | $1.6M | $1.6M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $27.6M | $88.1M | $123.4M | $150.0M | $119.8M | $74.5M | $75.2M | $75.5M | $113.6M |
| Accounts Payable | $4000 | $2.6M | $4.4M | $4.6M | $4.4M | $2.3M | $4.0M | $1.9M | $5.6M |
| Short-term Debt | 0 | 0 | 0 | 0 | $224000 | $495000 | 0 | 0 | $647000 |
| Total Current Liabilities | $1.6M | $4.5M | $8.3M | $6.2M | $6.8M | $6.1M | $7.2M | $8.1M | $14.0M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | $49.8M | $53.4M | $57.2M |
| Total Liabilities | $60.7M | $143.3M | $8.5M | $6.9M | $7.2M | $8.1M | $58.5M | $62.4M | $71.8M |
| Retained Earnings | -$35.1M | -$58.3M | -$113.5M | -$163.5M | -$206.3M | -$266.3M | -$326.0M | -$367.5M | -$430.6M |
| Total Equity | -$33.1M | -$55.2M | $114.9M | $143.1M | $112.6M | $66.3M | $16.8M | $13.1M | $41.8M |
| Total Debt | 0 | 0 | $514000 | $941000 | $698000 | $2.5M | $51.8M | $54.8M | $58.4M |
| Net Debt | -$26.9M | -$86.0M | -$119.3M | -$141.4M | -$113.4M | -$62.1M | -$14.2M | -$14.9M | -$47.6M |
| Working Capital | $25.9M | $83.5M | $114.2M | $142.5M | $112.1M | $65.7M | $65.8M | $65.8M | $97.9M |
Financial Health
| Debt / Equity | 7.79 |
| Current Ratio | 8.13 |
Profitability
| Return on Equity | -150.97% |
| Return on Invested Capital | -62.00% |
| Return on Assets | -55.53% |
| Gross Margin | 94.58% |
| Operating Margin | -3353.01% |
| Net Margin | -3585.62% |
Related companies: APLT · CRBP · CRDF · CYBN · ELTX · IPHA · MOLN
Explore sector: Healthcare · Biotechnology
More sections of MIST: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks